Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Weleda AG has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit. This indicates a focused and singular point of prosecution for the company's current pending matters. The concentration in 1 art unit suggests that the subject matter is specialized, requiring adherence to a specific set of technical guidelines and precedents within the biotech field.
MOREAU, NASHARA LOUISE is the busiest examiner for the portfolio, responsible for 1 pending office action. The company's current success in the biotech field is tied to the specific review and feedback of this 1 official. Practitioners should prioritize understanding the examination history of MOREAU, NASHARA LOUISE to effectively navigate the requirements of the Biotechnology & Pharmaceuticals sector. This centralized approach ensures that the strategy remains focused on a single set of examiner expectations, which can simplify the management of the company's pending intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOREAU, NASHARA LOUISE | 1 | 66.7% | -80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705158 | Cosmetic Composition Containing an Extract of Gentiana and Leontopodium and/or Centella | MOREAU, NASHARA LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705158 | Cosmetic Composition Containing an Extract of Gentiana and Leontopodium and/or Centella | MOREAU, NASHARA LOUISE | 1655 | §101§103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWeleda AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nashara Louise Moreau has the most, with 1 of Weleda AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
